And as a consequence, they are one of our core work streams. I’m not able to go in any particular detail, but for having an NDA with one or two of you, and we could go — we could do a deeper dive, but absent that, we are really constrained with regards to what we can say about this. There’s a question here from one of our long-term shareholders. Can you comment on the competitive landscape development over the past few years? It’s interesting. We pay a lot of attention to the competitive landscape. And one of the things I’d say about that is, if you — if we indicated we have a considerable number of patents pending issued, and in the pipe, we had third-party analytics performed for us. And I think a lot of this information exists on one of the PowerPoint presentations on the Investor page of our website.
Third-party analytics performed on our IP and the IP of competitors indicate that, we are the leading holder in the world. We’re the number one holder in the world when it comes to intellectual property relating to non-invasive continuous glucose monitoring. We continue to do that. While we do that, we look at what other people are doing. We look at that sometimes the public claims they’re making, which quite candidly are not supported by what we see behind the curtain in terms of their IP, in terms of what they’re doing. I think the thing I’ll say about this is that, it’s a very competitive marketplace. We see the competition quite candidly is including leading incumbents like Dexcom and Abbott Labs and Medtronic. They’re all competitors, because they have solutions.
We don’t think they’re the optimal solution, but they have solutions. They’re competitors. And there are these new entrants, which may claim to have a continuous glucose monitor. We pay very close attention to this. It’s a competitive landscape. We think we’ve got a leg up, but at the end of the day, we have to be ever diligent in paying attention to this. Just now, we’re alert to it. There’s a question here, will we show the second generation device in Italy? We’ve sort of spoken euphemistically about that in our press release in January when I said that the company will share updates on the latest developments of its non-invasive blood glucose monitor. I think you’re going to expect that, that we’ll be showing updates. The form that takes, all remains to be seen.
There is question about plans to develop revenues in 2024. Pete, do you want to speak to our thoughts about revenues in 2024?
Pete Conley: Sure, Ron. I think it’s clear our core focus is to take our current product family soon to be revealed second generation. You take us through the FDA path and clearance in the United States. What we’ve become increasingly aware of largely through market pull is that, there’s a rest of the world opportunity that represents a revenue path for us that doesn’t require the FDA. And so, we are actively and aggressively exploring that path to see if, in fact, we can generate revenue without having to go through the FDA. I can’t speak further to that currently, but it’s something we’re working on very hard.
Ron Erickson: I would say, that’s something that really kind of came naturally from people taking a look at the Generation 1 product and knowing, given its size and all the rest that it wasn’t a wearable continuous glucose monitor, but it perhaps had utility for doing spot checking in places where there’s a very high incidence of diabetes and a need for screening, especially in aspects of a less developed world. I think there’s another leg of the stool here that comes up, whether or not it will lead to revenue in 2024, all remains to be seen. It’s really a function of resource allocation, and that is — as you all know, we have a core focus on developing a continuous non-invasive blood glucose monitor. That’s happening with a technology that so many of you know is a platform technology.
It’s a technology that has the capacity to do other things. One of the things that as we have time and as we have cycles and focus here internally we think about, are there field of use licenses outside of the medical diagnostic arena where our platform technology can have utility? Or is there some low hanging fruit out there? Are there some pain points that are outside the medical diagnostic arena where our platform technology could be licensed to a third-party? That would certainly be a revenue generator. It’s something that we give some time and attention to. Whether or not that can come to fruition in ‘24 certainly remains to be seen. I wouldn’t count on it candidly, but I think it’s the kind of thing that comes up. It comes up in conversation with shareholders with some regularity, and I want you to know it’s something we’re certainly alert to and as we have cycles pay attention to.
I think I have just — we’ve it looks to me like we’ve covered, as it wouldn’t surprise you, we’ve had a about 20 plus people ask questions, and number of the questions are duplicates. I think, we’ve covered the primary categories here. I think, well, let me add a couple things, because these are just. So we’re going to ATTD big conference and one of the questions, well, why would you go to a conference in Europe? Well, candidly, it’s a global conference. Key opinion leaders, KOLs in the trade are going to be in Florence at this conference. And so we have the opportunity to meet them, to talk with them about what they are doing. We’re, by the way, hosting a luncheon with a global organization called Children with Diabetes. And there’ll be a number of key opinion leaders at that event.
So it’s an opportunity for us to meet people, to network and to showcase what we’re doing. So we’re going to make these two presentations. They will be made by Dr. Somers, as I indicated from Mayo Clinic. We’re going to be able to present the technology, talk about what we’re doing, talk about our clinical results, so it’s a global conference and a great opportunity for us. So we’re excited about that. Obviously, there will be some material announcements we hope that come out of that.
Ron Erickson: I think with that, I want to thank everyone. Thanks for your questions. It’s great to have engagement. I speak to a lot of you, Pete Conley speaks to a lot of you. We like keeping in touch and so don’t hesitate to reach out to us with any questions. Obviously, constrained by insider information, NDAs and all of those kinds of things, you all understand so well. But thank you for your support. Thank you for your engagement and, please be in touch. Thanks so much and all the very best to you.
Operator: Thanks, Ron. The conference call replay will be available on our website in the coming days. Thanks for your participation.
Ron Erickson: One more thing. I can’t let it go without saying Happy Valentine’s Day because in fact that is what it is today. Happy Valentine’s Day. All the very best to all of you.
